Get the Stockscreener App
33.65
9.23%
-3.53
Biohaven Ltd stock is traded at $33.65, with a volume of 1.28M.
It is down -9.23% in the last 24 hours and down -10.50% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$37.18
Open:
$36.95
24h Volume:
1.28M
Relative Volume:
1.39
Market Cap:
$3.53B
Revenue:
-
Net Income/Loss:
$-804.34M
P/E Ratio:
-3.576
EPS:
-9.41
Net Cash Flow:
$-531.06M
1W Performance:
-5.01%
1M Performance:
-10.50%
6M Performance:
-11.58%
1Y Performance:
-31.87%
1-Day Range:
$32.77
$36.95
1-Week Range:
$32.77
$38.23
52-Week Range:
$26.80
$62.21
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
33.69 | 3.53B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.07 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.05 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.23 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Biohaven’s BHV-1300 shows promise in IgG reduction By Investing.com - Investing.com South Africa
Biohaven’s BHV-1300 shows promise in IgG reduction - Investing.com
Biohaven reports ‘positive’ data from study of BHV-1300 - TipRanks
Earnings Flash (BHVN) BIOHAVEN LTD. Posts Q4 Loss $-1.71 Per Share, vs. FactSet Est of $-1.49 - Marketscreener.com
Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - StreetInsider.com
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - PR Newswire
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results - PR Newswire
Biohaven's Exciting Year Of Catalysts (NYSE:BHVN) - Seeking Alpha
(BHVN) Technical Pivots with Risk Controls - Stock Traders Daily
Biohaven's troriluzole gains FDA priority review for SCA - MSN
Biohaven (NYSE:BHVN) Now Covered by Deutsche Bank Aktiengesellschaft - MarketBeat
Biohaven stock rises following FDA review and Deutsche Bank's buy rating - MSN
Biohaven (NYSE:BHVN) Shares Gap UpWhat's Next? - MarketBeat
WCM Investment Management LLC Takes Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Mississippi to receive$162.2K of $59.7M Settlement Over Alleged Biohaven Kickbacks - Vicksburg Daily News
Biohaven Ltd. Receives FDA Priority Review for Troriluzole, Boosting Investor Confidence - TipRanks
Why Biohaven Stock Triumphed on Tuesday - The Motley Fool
Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck - Seeking Alpha
Biohaven, Ecolab, Firefly - TradingView
Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues (NYSE:BHVN) - Seeking Alpha
Biohaven stock rises following FDA review and Deutsche Bank’s buy rating - Investing.com Nigeria
Biohaven stock rises following FDA review and Deutsche Bank's buy rating By Investing.com - Investing.com South Africa
Biohaven Says FDA Grants Priority Review to Neurodegenerative Disorder Drug; Shares Rise - Marketscreener.com
Biohaven’s troriluzole NDA in spinocerebellar ataxia accepted by the FDA - TipRanks
Why Biohaven Ltd. Shares Are Tumbling? - TipRanks
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - Quantisnow
Jennison Associates LLC Makes New $3.64 Million Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
China Universal Asset Management Co. Ltd. Makes New $575,000 Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Kickback Case Settled For $59M - NewsBreak
SG Americas Securities LLC Has $336,000 Holdings in Biohaven Ltd. (NYSE:BHVN) - Defense World
Attorney General’s Office secures $2.3M in multistate action from Pfizer-owned company - Florida Politics
Biohaven Ltd.’s Promising Outlook for Troriluzole in Spinocerebellar Ataxia Amidst FDA Decision - TipRanks
Biohaven FY2025 EPS Forecast Decreased by Leerink Partnrs - MarketBeat
(BHVN) Technical Data - Stock Traders Daily
Leerink Partnrs Decreases Earnings Estimates for Biohaven - Defense World
Nebraska Joins in Settling Kickback Allegations against Biohaven Pharmaceutical Holding Company Ltd. - Rural Radio Network
Nebraska joins in settling kickback allegations against Biohaven - norfolkneradio.com
Pfizer to pay nearly $60M over kickbacks for migraine drug developed by New Haven-based Biohaven - Hartford Business Journal
Multiple System Atrophy (MSA) Market 2025-2032 Business - openPR
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.93%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):